Early trial yields promising results for NIH's dengue vaccine

01/25/2013 | United Press International

A Phase I trial found the NIH's experimental dengue vaccine TetraVax-DV was safe and triggered strong antibody responses in most of the 112 participants. Four combinations were tested, and one called TV003 activated the most balanced response, according to a report in the Journal of Infectious Diseases. More work is needed, but the results are reason for cautious optimism, said National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci.

View Full Article in:

United Press International

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ